Esophageal Cancer – Epidemiology – Epidemiology – Esophageal Cancer – Mature Markets

Clarivate Epidemiology’s coverage of esophageal cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of esophageal cancer for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report. In addition to forecasting incident and prevalent patient populations, we estimate the number of drug-treatment opportunities in specific lines of therapy in the major mature pharmaceutical markets.

Clarivate Epidemiology’s esophageal cancer forecast will answer the following questions:

• How will changes in the levels of exposure to known risk or protective factors affect the number of people diagnosed with esophageal cancer each year?
• How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of esophageal cancer over the forecast period?
• How will improvements in survival change the number of first-line drug-treatment opportunities for esophageal cancer?
• How will decreasing recurrence risk change the number of first-line drug-treatment opportunities for esophageal cancer?
• Of all people diagnosed with esophageal adenocarcinoma and squamous cell carcinoma, how many in each of the major pharmaceutical markets are drug-treated?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods. In addition, we provide a graph depicting the patient flow between or within different disease states for the countries considered in this report. These patient-flow diagrams are provided at the regional level but may be requested for any specific country or forecast year.

Clarivate Epidemiology provides at least 10 years of forecast data for the following esophageal cancer patient populations:

• Diagnosed incident cases of esophageal cancer.
• Diagnosed incident cases of esophageal cancer by histological subtype.
• Diagnosed esophageal adenocarcinoma incident cases by HER2 status.
• Diagnosed incident cases of esophageal cancer by stage at diagnosis.
• Diagnosed incident cases of esophageal adenocarcinoma, squamous cell carcinoma, and other esophageal cancers by stage at diagnosis.
• Diagnosed prevalent cases of esophageal cancer.
• Diagnosed prevalent cases of esophageal cancer by histological subtype.
• Diagnosed first-line unresectable/metastatic HER2-positive esophageal adenocarcinoma drug-treatable population.
• Diagnosed first-line unresectable/metastatic HER2-negative esophageal adenocarcinoma drug-treatable population.
• Diagnosed first-line unresectable/metastatic esophageal squamous cell carcinoma drug-treatable population.
• Diagnosed drug-treated first-line unresectable/metastatic HER2-positive esophageal adenocarcinoma population.
• Diagnosed drug-treated first-line unresectable/metastatic HER2-negative esophageal adenocarcinoma population.
• Diagnosed drug-treated first-line unresectable/metastatic HER2-negative esophageal squamous cell carcinoma population
• … and many more (details available on request).

Note: Coverage may vary by country.